HPB Great Debate: Neoadjuvant Therapy Should be Routinely Given for High-risk Intrahepatic Cholangiocarcinoma

Moderator(s)

• 

  Shishir Maithel, MD

  Professor of Surgery
  Emory
  Atlanta, GA, United States

  Disclosure information not submitted.

Presentations:

• 8:40 AM – 8:57 AM

  PRO: Neoadjuvant Therapy Should be Routinely Given for High-risk Intrahepatic Cholangiocarcinoma
  

  Debater: Hop S. Tran Cao, MD (he/him/his) – The University of Texas MD Anderson Cancer Center
• 8:57 AM – 9:14 AM

  CON: Neoadjuvant Therapy Should be Routinely Given for High-risk Intrahepatic Cholangiocarcinoma
  

  Debater: Cristina Ferrone, MD (she/her/hers) – Cedars-Siani
• 9:14 AM – 9:30 AM

  Rebuttal and Discussion
  

  Panelist: Hop S. Tran Cao, MD (he/him/his) – The University of Texas MD Anderson Cancer Center

  Panelist: Cristina Ferrone, MD (she/her/hers) – Cedars-Siani